Immuneering Corporation (IMRX) Gross margin 2020–2022
Immuneering Corporation (IMRX) gross margin by fiscal year — reported gross profit divided by reported revenue.
50.1%FY2022 · since FY2020: 44.6% → 50.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2022 | 50.1% | +5.5 pp |
| FY2021 | 44.6% | -0.0 pp |
| FY2020 | 44.6% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More IMRX financial trends
IMRX RevenueIMRX Net incomeIMRX Net marginIMRX Gross profitIMRX Operating incomeIMRX Operating marginIMRX Operating cash flowIMRX Free cash flowIMRX Capital expendituresIMRX Return on equityIMRX Stock buybacksIMRX Dividends paidIMRX Total assetsIMRX Total liabilitiesIMRX Shareholders’ equityIMRX overview →